Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
about
ARID1A mutations in endometriosis-associated ovarian carcinomasBRCAness: finding the Achilles heel in ovarian cancerMolecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemiaOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengePARP inhibitors in the management of breast cancer: current data and future prospectsPatient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatmentPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tubeCaspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.A current review of targeted therapeutics for ovarian cancer.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damageProteomics as a guiding tool for more effective personalized therapy.BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifierTargeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.Potential markers for detection and monitoring of ovarian cancer.Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.The ups and downs of DNA repair biomarkers for PARP inhibitor therapiesTherapeutic advances in women's cancersThe new face of ovarian cancer modeling: better prospects for detection and treatment.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Therapeutic strategies in epithelial ovarian cancer.Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapyMinireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.
P2860
Q24610484-935DD940-7442-456C-83CF-7DE5BE41D5ABQ24630872-A49ADE07-F49D-4EC4-B302-B1B5DD00E587Q24657303-6F5ECE80-6C9B-4228-BD4E-1003D191EA12Q26747279-14DE8828-9037-4EB0-9C11-85E007B35062Q26777846-55CAACEB-0348-402A-AF0E-990AB39EB87FQ26798352-857BBC12-54FD-4971-A708-7328A8DA3FD6Q26829125-BCB77A26-BA3C-4BAD-974B-69690D3EC7DAQ27027503-9DA40F67-46A5-42D5-820A-208A366B0058Q27851709-55AF6A6C-9674-41E4-9670-BE0085FA1A24Q30240245-D059B9B8-722C-4E07-A5E1-E12B9EBE94D5Q30430198-54289D75-4E75-48FE-B7B8-E2A0BFCF590BQ30448232-1046A594-B505-44CE-A7A0-73B2EF04A675Q33508232-695C32FE-8DA8-47FA-A018-181517C443B5Q33510967-F3D610BD-A2EB-4C33-968F-AFA3099AA014Q33529488-7DD44703-F645-480A-A737-25A91999A223Q33557369-16D72BF6-D004-4F26-AD31-1500B7515D1DQ33580777-D6D13B10-F4CA-468C-9FED-44DF6BBBF63DQ33580998-0196C311-6C5A-4060-BE9E-B455406C7CA9Q33621141-C14A468E-D98E-4202-ADCA-4EE3B9137857Q33693203-08391936-448F-4596-BA66-6A19C7D940E9Q34049234-227BEC81-6DBB-4571-8057-A4CECC9DC741Q34215904-D09203B7-75D5-4BC2-AE2A-75A380FBACF6Q34253391-F8DF6F46-D529-4597-8BCE-8368A0ADDD63Q34287721-398FA677-622A-49BF-9347-680CE47C6AB5Q34305493-03CA9992-2918-4398-B070-E007E02F3F9DQ34342840-D06C2B93-FE88-4678-ADE0-71D4DDE3A277Q34480451-3B20A035-C495-4D9B-A0B3-FA45BD0A59A2Q34589804-B7248966-9E17-4C86-9985-1BF639F34B75Q34720998-2DD8A18F-A9B6-4602-A99F-4C1B6135C14EQ34878868-8128EFC8-4EAD-4EE4-81F4-643807868BD0Q34960174-77DEF9A5-2A14-4738-97CE-06BB73506903Q35076298-17134444-4F31-4557-B661-823DE77C6148Q35232277-5BC6C9C6-F851-4016-BDCF-4FEABD88E7C0Q35418973-297B8876-5697-4E4E-9961-E30A92A50048Q35507860-32C0811D-AB69-4434-8DD8-F8F3EA80E9D3Q35837949-AEA8931A-CABC-42C6-A54A-7ED4E1013DDAQ35845484-A1F37C83-9A48-4A6B-8A9E-A44B00A28AA4Q35851488-AB785B38-7DE8-488D-ACF3-21AFA5D772C2Q35872796-2E680E93-B116-4F02-95FB-281FD7C9ED6FQ36043441-AA101BC8-7B1C-45B7-9BE9-D664802D7C25
P2860
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@ast
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@en
Ovarian carcinomas with geneti ...... tinct molecular abnormalities.
@nl
type
label
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@ast
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@en
Ovarian carcinomas with geneti ...... tinct molecular abnormalities.
@nl
prefLabel
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@ast
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@en
Ovarian carcinomas with geneti ...... tinct molecular abnormalities.
@nl
P2093
P2860
P356
P1433
P1476
Ovarian carcinomas with geneti ...... stinct molecular abnormalities
@en
P2093
Alessandro De Luca
Armelle Troussard
C Blake Gilks
David G Huntsman
Dianne M Miller
Doug Horsman
Joshua Z Press
Katherine A Blood
Malek Faham
P2860
P2888
P356
10.1186/1471-2407-8-17
P407
P577
2008-01-22T00:00:00Z
P5875
P6179
1003338054